Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis therapy. A practical guide

B W van Oosten1, L Truyen, F Barkhof

  • 1Department of Neurology, Free University Hospital, Amsterdam, The Netherlands.

Drugs
|February 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What if it is the eyes? The effect of eye movement disorders on cognitive testing in MS.

Journal of neurology·2026
Same author

Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).

Journal of neurology·2025
Same author

The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis.

Multiple sclerosis and related disorders·2024
Same author

Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.

Journal of the neurological sciences·2024
Same author

Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases.

Multiple sclerosis and related disorders·2020
Same author

A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.

Multiple sclerosis and related disorders·2020
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Multiple sclerosis (MS) pathogenesis involves immune dysfunction. While immunosuppressants show potential, interferon-beta-1b offers a safer alternative for managing MS relapses and progression.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology

Background:

  • Immune system dysfunction is central to multiple sclerosis (MS) pathogenesis.
  • Current treatments for MS include immunosuppressive drugs with significant side effects.
  • Interferon-beta-1b has emerged as a treatment option with a better safety profile.

Purpose of the Study:

  • To review the role of immunological disturbances in MS pathogenesis.
  • To discuss current and emerging therapeutic strategies for MS.
  • To highlight the importance of symptomatic management and future treatment directions.

Main Methods:

  • Review of existing literature on MS pathogenesis and treatment.
  • Analysis of the efficacy and safety profiles of various MS drugs.
  • Discussion of novel therapeutic targets and diagnostic tools.

Related Experiment Videos

Main Results:

  • Immunosuppressive agents may slow MS progression but carry risks.
  • Interferon-beta-1b effectively reduces exacerbation rates with fewer adverse effects.
  • Symptomatic treatments, rehabilitation, and psychosocial support are vital for MS patient management.

Conclusions:

  • Future MS therapies will focus on modulating immune response specificity or activation.
  • Magnetic resonance imaging (MRI) will be crucial for assessing new therapeutic agent efficacy.
  • A multi-faceted approach combining disease-modifying treatments and symptomatic care is essential for MS management.